Long-Standing Thyroid Eye Disease
Solving the TED Puzzle: Answering Your Questions on Diagnosis to Decision-Making
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease Mastery: Multidisciplinary Approaches to Diagnosis and Treatment
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease: Improving Clinical Practice With Real-World Insights
This activity is supported by educational funding provided by Amgen.
Thyroid Eye Disease: Navigating Diagnosis and Treatment in the Real World - A Podcast Series
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comprehensive Thyroid Eye Disease Management: Beyond the Bulge
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Thyroid Eye Disease 360° Guidance: Surgical Procedures, Research Trends, and Case Challenges
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comanagement of Thyroid Eye Disease for the Ophthalmology and Optometry Provider
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comanagement of Thyroid Disorders for the Endocrinology Provider
This activity is supported by and educational grant from Horizon Therapeutics USA, Inc.
Teprotumumab reduces proptosis in long-standing, stable thyroid eye disease
Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.